166 related articles for article (PubMed ID: 10999465)
21. Plasma TIMP1 level is a prognostic factor in patients with liver metastases.
Bunatova K; Pesta M; Kulda V; Topolcan O; Vrzalova J; Sutnar A; Treska V; Pecen L; Liska V
Anticancer Res; 2012 Oct; 32(10):4601-6. PubMed ID: 23060593
[TBL] [Abstract][Full Text] [Related]
22. MMP, VEGF and TIMP as prognostic factors in recurring bladder cancer.
Wieczorek E; Jablonowski Z; Tomasik B; Konecki T; Jablonska E; Gromadzinska J; Fendler W; Sosnowski M; Wasowicz W; Reszka E
Clin Biochem; 2015 Dec; 48(18):1235-40. PubMed ID: 26197083
[TBL] [Abstract][Full Text] [Related]
23. Plasma concentration of tissue inhibitor of matrix metalloproteinase 1 in patients with colorectal carcinoma.
Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Takemiya S; Yanoma S; Noguchi Y; Takanashi Y
Br J Surg; 2001 Dec; 88(12):1596-601. PubMed ID: 11736971
[TBL] [Abstract][Full Text] [Related]
24. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) in preoperative serum as independent prognostic markers in patients with colorectal cancer.
Dragutinović VV; Radonjić NV; Petronijević ND; Tatić SB; Dimitrijević IB; Radovanović NS; Krivokapić ZV
Mol Cell Biochem; 2011 Sep; 355(1-2):173-8. PubMed ID: 21541674
[TBL] [Abstract][Full Text] [Related]
25. Cytokeratins and carcinoembryonic antigen in diagnosis, staging and prognosis of colorectal adenocarcinoma.
Fernandes LC; Kim SB; Matos D
World J Gastroenterol; 2005 Feb; 11(5):645-8. PubMed ID: 15655814
[TBL] [Abstract][Full Text] [Related]
26. Levels of matrix metalloproteinase-1 and tissue inhibitors of metalloproteinase-1 in gastric cancer.
Kemik O; Kemik AS; Sümer A; Dulger AC; Adas M; Begenik H; Hasirci I; Yilmaz O; Purisa S; Kisli E; Tuzun S; Kotan C
World J Gastroenterol; 2011 Apr; 17(16):2109-12. PubMed ID: 21547130
[TBL] [Abstract][Full Text] [Related]
27. Association between serum levels of pro-metalloproteinase 1, tissue inhibitor of metalloproteinases 1 and 2 and prevalent cardiovascular disease in a population-based study.
Panayiotou AG; Kamilari E; Griffin M; Tyllis T; Georgiou N; Bond D; Hoppensteadt D; Fareed J; Nicolaides A
Int Angiol; 2013 Dec; 32(6):599-604. PubMed ID: 24212294
[TBL] [Abstract][Full Text] [Related]
28. The Significance of Combined Measurement of p53 Antibody and other Tumor Markers for Colorectal Cancer after Curative Resection.
Kawahara D; Fujita F; Hayashi H; Matsuyama T; Eguchi S
Hepatogastroenterology; 2015 May; 62(139):624-8. PubMed ID: 26897942
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor.
Mroczko B; Lukaszewicz-Zajac M; Wereszczynska-Siemiatkowska U; Groblewska M; Gryko M; Kedra B; Jurkowska G; Szmitkowski M
Pancreas; 2009 Aug; 38(6):613-8. PubMed ID: 19629003
[TBL] [Abstract][Full Text] [Related]
30. Pre-treatment serum and plasma levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) in gastric cancer patients.
Mroczko B; Groblewska M; Łukaszewicz-Zajac M; Bandurski R; Kedra B; Szmitkowski M
Clin Chem Lab Med; 2009; 47(9):1133-9. PubMed ID: 19728856
[TBL] [Abstract][Full Text] [Related]
31. Preoperative plasma TIMP-1 is an independent prognostic indicator in patients with primary colorectal cancer: a prospective validation study.
Birgisson H; Nielsen HJ; Christensen IJ; Glimelius B; Brünner N
Eur J Cancer; 2010 Dec; 46(18):3323-31. PubMed ID: 20619633
[TBL] [Abstract][Full Text] [Related]
32. Matrix metalloproteinases MMP1, MMP2, MMP9 and their tissue inhibitors TIMP1, TIMP2, TIMP3 in head and neck cancer: an immunohistochemical study.
Pietruszewska W; Bojanowska-Poźniak K; Kobos J
Otolaryngol Pol; 2016 Jun; 70(3):32-43. PubMed ID: 27386931
[TBL] [Abstract][Full Text] [Related]
33. Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients.
Toiyama Y; Miki C; Inoue Y; Okugawa Y; Tanaka K; Kusunoki M
Int J Cancer; 2009 Oct; 125(7):1657-62. PubMed ID: 19569242
[TBL] [Abstract][Full Text] [Related]
34. Normalization of serum p53 antibody levels in patients after curative resection for colorectal cancer.
Kawahara H; Watanabe K; Enomoto H; Toyama Y; Akiba T; Yanaga K
Anticancer Res; 2013 May; 33(5):2221-5. PubMed ID: 23645779
[TBL] [Abstract][Full Text] [Related]
35. Time-dependency of the prognostic effect of carcinoembryonic antigen and p53 protein in colorectal adenocarcinoma.
Diez M; Pollan M; Müguerza JM; Gaspar MJ; Duce AM; Alvarez MJ; Ratia T; Herñandez P; Ruiz A; Granell J
Cancer; 2000 Jan; 88(1):35-41. PubMed ID: 10618603
[TBL] [Abstract][Full Text] [Related]
36. The sCEA molecule suppressive role in NK and TH1 cell functions in colorectal cancer.
Pellegrini P; Berghella AM; Del Beato T; Maccarone D; Cencioni S; Adorno D; Casciani CU
Cancer Biother Radiopharm; 1997 Aug; 12(4):257-64. PubMed ID: 10851473
[TBL] [Abstract][Full Text] [Related]
37. High plasma TIMP-1 and serum CEA levels during combination chemotherapy for metastatic colorectal cancer are significantly associated with poor outcome.
Aldulaymi B; Byström P; Berglund A; Christensen IJ; Brünner N; Nielsen HJ; Glimelius B
Oncology; 2010; 79(1-2):144-9. PubMed ID: 21150229
[TBL] [Abstract][Full Text] [Related]
38. Changes in plasma TIMP-1 levels after resection for primary colorectal cancer.
Frederiksen C; Lomholt AF; Davis GJ; Dowell BL; Blankenstein MA; Christensen IJ; Brünner N; Nielsen HJ
Anticancer Res; 2009 Jan; 29(1):75-81. PubMed ID: 19331135
[TBL] [Abstract][Full Text] [Related]
39. Serum-derived carcinoembryonic antigen (CEA) activates fibroblasts to induce a local re-modeling of the extracellular matrix that favors the engraftment of CEA-expressing tumor cells.
Abdul-Wahid A; Cydzik M; Fischer NW; Prodeus A; Shively JE; Martel A; Alminawi S; Ghorab Z; Berinstein NL; Gariépy J
Int J Cancer; 2018 Oct; 143(8):1963-1977. PubMed ID: 29756328
[TBL] [Abstract][Full Text] [Related]
40. Detection and monitoring of serum p53 antibodies in patients with colorectal cancer.
Hammel P; Boissier B; Chaumette MT; Piedbois P; Rotman N; Kouyoumdjian JC; Lubin R; Delchier JC; Soussi T
Gut; 1997 Mar; 40(3):356-61. PubMed ID: 9135525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
